Philip James Wealth Mangement LLC Invests $475,000 in United Therapeutics Co. (NASDAQ:UTHR)

Philip James Wealth Mangement LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,325 shares of the biotechnology company's stock, valued at approximately $475,000.

Several other hedge funds have also recently modified their holdings of UTHR. LSV Asset Management raised its stake in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock worth $307,837,000 after buying an additional 436,851 shares in the last quarter. Swedbank AB acquired a new stake in United Therapeutics in the first quarter valued at $97,316,000. Canada Pension Plan Investment Board lifted its holdings in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company's stock valued at $41,533,000 after acquiring an additional 153,700 shares during the period. Pacer Advisors Inc. boosted its position in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock worth $178,972,000 after purchasing an additional 92,240 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of United Therapeutics by 49.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company's stock worth $88,089,000 after purchasing an additional 91,597 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now directly owns 3,675 shares of the company's stock, valued at $1,384,115.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at $44,743.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 510 shares of the business's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 96,422 shares of company stock worth $35,251,428 over the last three months. 11.90% of the stock is owned by insiders.

United Therapeutics Trading Up 1.8 %

Shares of NASDAQ UTHR traded up $7.43 on Friday, reaching $410.00. 498,738 shares of the company traded hands, compared to its average volume of 464,869. The stock has a market capitalization of $18.31 billion, a PE ratio of 17.68, a P/E/G ratio of 1.16 and a beta of 0.56. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The company has a 50 day moving average of $358.27 and a 200 day moving average of $320.94.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.38 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Bank of America lowered their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating on the stock in a research note on Thursday, August 1st. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group increased their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.